Jiangsu Berkgen Biopharmaceutical

Berkgen Biopharma is a clinical-stage biotechnology company based in Nanjing, China, specializing in the development of next-generation oncolytic virus therapies and gene-modified cell therapies. The company leverages its proprietary o-VP platform to engineer viruses that selectively replicate in and destroy cancer cells while stimulating a systemic anti-tumor immune response. Its lead candidate, BG-L-01, is an oncolytic herpes simplex virus currently being evaluated in clinical trials for the treatment of advanced solid tumors, including hepatocellular carcinoma. Berkgen aims to address unmet medical needs in oncology through innovative viral vector engineering and combination therapy strategies.